

Phase II (New Entities)

Allergy Immunotherapy Tablet³

Dust Mite Allergies

Allergy Immunotherapy Tablet³

Ragweed Allergies

AMPA PAM

*ADHD
Depression*

CHK-1 Inhibitor

Cancer

CXCR2 Receptor Antagonist

COPD

Dinaciclib*

Cancer

Glycine Uptake Inhibitor

*Alcohol Dependence
Schizophrenia*

Mometasone/Oxymetazoline

Allergic Rhinitis

Narlaprevir**

Hepatitis C

Pleconaril

Common Cold and Asthma Exacerbations

Preladenant

Parkinson's Disease

**Robatumumab
(Anti-IGF-1R Antibody)**

Cancer

Topical Antifungal

Onychomycosis

Phase II (Value Adding Projects)

NOXAFIL

I.V. Formulation

Vicriviroc

HIV Infection (Treatment Naive)

Phase III (New Entities)

Acadesine

Ischemia-Reperfusion Injury

Allergy Immunotherapy Tablet³

Grass Pollen Allergies

Boceprevir

Hepatitis C

Esmirtazapine

*Insomnia
Hot Flashes*

Thrombin Receptor Antagonist

*Acute Coronary Syndrome
Secondary Prevention*

Vicriviroc

HIV Infection (Treatment Experienced)

Phase III (Value Adding Projects)

**Mometasone/Formoterol
Combination**

COPD

NASONEX

Rhinosinusitis

SIMPONI (Golimumab)¹

Ulcerative Colitis

VYTORIN² - Outcomes Trials

*SHARP - Renal Disease
IMPROVE-IT - Acute Coronary Syndrome*

Regulatory Application Filed (New Entities)

Corifollitropin alfa

Controlled Ovarian Stimulation (EU)

**Mometasone/Formoterol
Combination**

Asthma (U.S., EU)

▶ **NOMAC/E2**

Contraceptive (EU)

SAPHRIS (Asenapine)

*Schizophrenia (EU)
Bipolar I Disorder (EU)*

Sugammadex

Anesthesia (U.S., Japan)

Regulatory Application Filed (Value Adding Projects)

▶ **IMPLANON**

Next-generation contraceptive rod (U.S., EU)

▶ **NASONEX**

Congestion (U.S.)

NOXAFIL

Serious Fungal Infections (U.S.)

PEGINTRON

Malignant Melanoma (U.S.)

TEMODAR

I.V. Formulation (Japan)

Investor Contacts:

Janet Barth (908) 298-7011

Joe Romanelli (908) 298-7904

▶ Phase advance

¹ International rights only

² J.V. with Merck

³ North American rights only

* Formerly CDK Inhibitor

** Formerly Protease Inhibitor (SCH 900518)

The SGP Product Pipeline is solely intended to provide to investors general information regarding Schering-Plough projects in development and, for this reason, the information is not represented to be complete. Due to market factors and the nature of the development and approval process, the information - including the status of these projects - is subject to change. The Pipeline speaks only to the date hereof. Schering-Plough does not assume any duty to update this information. "International Status" does not necessarily imply that the company will be marketing the compound in all major countries.

The trademarks indicated by CAPITAL LETTERS are the property of, licensed to, promoted or distributed by Schering-Plough, its subsidiaries or related companies.

Pipeline Updates

Phase II

Rolapitant

As announced on October 13, 2009, Schering-Plough entered into a definitive agreement with OPKO Health, Inc. to divest assets relating to its neurokinin-1 (NK-1) receptor antagonist program, including Rolapitant. Closing of the transaction between OPKO and Schering-Plough is subject to completion of the merger between Schering-Plough and Merck & Co., Inc.

Regulatory Application Filed

Mometasone/Formoterol Combination

Schering-Plough announced on July 22, 2009 that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate has been filed in the United States and accepted for review by the U.S. Food and Drug Administration (FDA). Schering-Plough is seeking marketing approval from the FDA of the mometasone furoate/formoterol fumarate combination for the maintenance treatment of asthma in patients 12 years of age and older.

The company also announced that the European Medicines Agency (EMA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older on August 26, 2009.

NOMAC/E2

On August 26, 2009 Schering-Plough announced that the EMA has validated the MAA for norgestrel acetate (2.5 mg) / 17 beta-estradiol (1.5mg), a combined oral contraceptive (COC) containing a unique combination of a natural estrogen identical to the estrogen produced by a woman's own body and a selective progestin.

SAPHRIS (Asenapine)

On August 14, 2009 Schering-Plough announced that the FDA has approved SAPHRIS (asenapine) sublingual tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. SAPHRIS can be used as a first-line treatment and is the first psychotropic drug to receive initial approval for both of these indications simultaneously.

SIMPONI (Golimumab)¹

The European Commission approved SIMPONI as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis, active and progressive psoriatic arthritis and severe, active ankylosing spondylitis on October 6, 2009.

Regulatory Application Filed (Value Adding Projects)

IMPLANON

In September 2009, the U.S. FDA and EMA both accepted for review the regulatory applications for IMPLANON. The company is seeking approval for a next generation single-rod implantable treatment for women to prevent pregnancy.

NASONEX

The FDA accepted for review the supplemental application for the treatment of congestion in September 2009.

Approvals

ASMANEX (DPI)

Asthma [Japan 7/09]
Pediatric Asthma [U.S. 2/08]

AROGLYCEM¹

Hypoglycemia due to hyperinsulinism
[Japan 4/08]

BEPRICOR

Atrial Fibrillation [Japan 10/08]

BRIDION (Sugammadex)

Reversal of neuromuscular blockade
[EU 7/08]

CAELYX¹

Multiple Myeloma [EU 11/07]

CLARINEX-D 12 Hour

Allergic Rhinitis with Congestion
[U.S. 2/06]

GANIREST

Prevention of premature ovulation during
controlled ovarian stimulation [Japan 7/08]

NASONEX

Allergic Rhinitis [Japan 7/08]
Unscented [EU 4/07]

NOXAFIL

Oropharyngeal Candidiasis (OPC) [U.S.
10/06, EU 11/06]
Prevention of Invasive Fungal Infections
[U.S. 9/06, EU 11/06]

PEGINTRON/REBETOL

Retreatment [U.S. 3/09]
Weight-Based Dosing [U.S. 3/08]
HCV / HIV coinfection [EU 6/07]

REMERON

Anti-depressant [Japan 7/09]

REMICADE¹

Reduction of Ulcerative Colitis surgical
procedures [EU 4/08]
Pediatric Crohn's Disease [EU 3/07]
Second-line Crohn's Disease [EU 10/06]
Psoriatic Arthritis Monotherapy [EU 3/06]

SAPHRIS

Schizophrenia [U.S. 8/09]
Bipolar I Disorder [U.S. 8/09]

SIMPONI (Golimumab)¹

Rheumatoid Arthritis [Canada 4/09, EU 10/09]
Psoriatic Arthritis [Canada 4/09, EU 10/09]
Ankylosing Spondylitis [Canada 4/09, EU 10/09]

TEMODAR

I.V. Formulation [U.S., EU 3/09]
Oral Sachet [EU 1/09]
Astrocytoma / Glioblastoma Multiforme
[Japan 7/06]

VYTORIN²

Rosuvastatin data / labeling [U.S. 10/06]
Atorvastatin data / labeling [U.S. 3/06]

ZEMURON

Pediatric Indication [8/08]

ZETIA²

Lipid Lowering Monotherapy [Japan 4/07]

¹International rights only²J.V. with Merck³North American rights only